Investment presentation for investment bank and high net worth offices

1. Canadabis TSX.V
Securing the lion’s share of the market in
Western Canada

2. This corporate document contains “forward-looking statements” and “forward-looking information” (collectively, “forward-looking information”) within the meaning of applicable securities legislation.” Thereafter, all
references should be to “forward-looking information”). This corporate document may use words such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”,
“estimate”, “outlook”, and other similar expressions to identify forward-looking statements. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-
looking statements in this corporate document, and, accordingly, investors should not place undue reliance on any such forward-looking statements. Forward-looking information involves significant risks,
assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements and accordingly, should
not be read as guarantees of future performance or results. Any forward-looking statements speak only as of the date on which such statement is made and each of the Company and the Agents disclaims any
intention or obligation to update or revise any forward-looking information, where as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to
time, and it is not possible for management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Forward looking Statements
Legal Disclaimer
This document provides a description of Stigma Pharmaceutical its affiliates (together, the “Company”)and their respective businesses. Prospective investors are encouraged to obtain independent legal advice
concerning any investment in securities of the Company and should not base their decision on whether to invest in the Company solely upon the material provided herein. There are no representations or warranties
made herein by the Company or the agents, if any, of the proposed offering of any securities or debt instruments in the Company (the “Agents”) and investors will only be able to rely on the representations and
warranties contained in the subscription agreement to be entered into at the time of sale of the securities. There are certain risks inherent in an investment in the securities of the Company that prospective investors
should carefully consider before investing in the securities of the Company. This document constitutes an offering of the securities described herein only in those jurisdictions and to those persons where and to
whom they may be lawfully offered for sale, and only by persons permitted to sell these securities. This document is not, and under no circumstances is it to be construed as, an advertisement or a public offering of
these securities. This document is personal to each offeree and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire any of the securities referred to herein.
No securities regulatory authority or similar authority has reviewed or in any way passed upon the presentation or the merits of these securities and any representation to the contrary is an offence. This document
has been prepared for information purposes only in order to assist prospective investors in evaluating an investment in the Company. No representation, warranty or undertaking, express or implied, is made and no
responsibility or liability is accepted by the Agents as to the accuracy or completeness of the information contained herein or any other information, representation, warranty or undertaking, express or implied,
made by the Company in connection with the offering of securities described herein.

3. Consolidation of Canada’s West
through the acquisition of vertically
integrated channels and leveraging a
regulation-proof distribution system

4. The Hurdles of the Ecosystem
Seed to sale is complexified for a growth-
centric aggregator, allowing for product
quality and supply imbalances across
provincial lines.
The first to solve this conundrum will
be the market leader
Man. Sask. Alberta BC

5. The Western Opportunity
Patients Licenses
East
West
Alberta

6. What
Crosses
Borders?
Most of the physical
elements necessary in
selling Cannabis
Brands, Packaging,
knowledge and
influence

7. The Founders
With decades of wins under their belt a new business model in an exciting industry
called out to these seasoned enterprise builders.
Travis McIntyre
President, CEO/COO
● Co-Founded Stigma Pharmaceuticals in 2014
● Developed and perfected 14 of the cannabinoid
profiles proven to be the most sought after by
consumers
● Success Oil and Gas founder and executive
Kim McIntyre
VP, Sales and Administration
● Co-Founded Stigma Pharmaceuticals in 2014
● Developed the administrative work processes on
which to scale
● Tested sales channels in conjunction with
growing regulatory constraints

8. The Foundation
You are only as strong as your weakest link
Charlotte Murray
QA/QCM and ARIPC
● BSc in Medical Laboratory Science,
● Registered technologist with the
Canadian Society of Medical
Laboratory Technology
● HPS Lifetime Achievements Award,
SAIT Polytechnics Instructor
Excellence Award, SAIT 40 Year
Service Award, SAIT special
contribution and Achievement
Award.
John Karroll
Advisory Board
● Sat on numerous exploratory
consulting boards that created the
past and current medical
regulations as well as the current
recreational legislature.
● CEO of Trichome Consulting
Services which specializes in
assisting applicants in navigating
the regulatory requirements for
license approval.
● Trichome Consulting Services
currently counts as customers the
federal and state governments of
Canada, Australia and South Africa
among others.
John Bouw
Advisory Board
● 2nd Generation Dutch Greenhouse
builder.
● Planned, built and operated a top
tier wholesale greenhouse for
nearly 3 decades, in Alberta.
● Supplied Canadian Tire, Wal-Mart
and other large scale retailers with
plant products

9. The Network
It takes a village to raise a child - African Proverb
Branding and Retail
Product Development
Patient services and regulatory
compliance
A manufacturer and distributor of
gardening and hydroponic supplies

10. Milestones
January 2014
Stigma Pharmaceutical
is founded
March
2018
Phase 1 Facility
under construction
November 2018
Cultivation License
July 2018
Canadabis
binding LOI
October 2018
Planned entry on
TSX.v
2014 2018 Mar Apr May Jun Jul Aug Sept Oct Nov Dec
August 2018
Phase 1 Facility
projected completion

11. License to Cultivate
November 2018
License to Sell
February 2019

12. September 2018
SevenTails Cannabis offer
(Branding and edibles) BC LP
October 2018
Web client list offer
(8,000/$5 million sales)
March 2019
Saskatchewan
Master License Agreement
June 2019
Manitoba Master
License Agreement
Sept Oct Nov Dec Jan Feb Mar Apr May June July August
Acquisition Targets
Feb 2019
License to Sell
Cannabis Act

13. The
Vertical’s
Retail and
Web
Wholesale
Brands and
Licensing
Stigma
Retail
Stigma Grow
Stigma Cannabis

14. Revenue
model
B2C through company owned retail and web channels of a
variety of brands and products including Stigma brands
purchased directly from internal wholesale, liquor boards or
master license holders, depending on the jurisdiction.
Wholesale to liquor boards and other Licensed Producers of
Stigma branded and raw products.
Selling branded packaging materials to a chosen provincial
master licensee. Our branded products will sold to the
provincial liquor boards or direct to Stigma retail locations
depending on the jurisdictions rules.
Retail and
Web
Wholesale
Brands and
Licensing

15. Brand
Control
● In order to protect the value of Stigma Brands our Master Grower and QA/QI
professional will regularly visit Stigma facilities and holders of Master Licenses of
Stigma Products.
● The Master license holders will purchase branded packaging from Stigma
Cannabis and only use Stigma Grow approved raw products, strains and recipes.
● This will ensure that regardless of the jurisdictions rules, the brands will be
nationally recognized with a Big Mac benchmark quality that consumers will
recognize regardless of their travels

16. $
$ $$$
$
$
$$
The Supply
Chain
Raw Wholesale
Other Brands
Stigma Brands
Stigma Retail
Provincial LC
Stigma Grow
Master Licensee
Products

17. The
Organization
Advisory
Board
Executive
Officers
Administration
Sales And
Marketing
Operations and
Licensing
QI/QA
Master Grower Sourcing and
Logistics
Delivery
Advertising
Package mfg
Retail
Patient
Services
Patient
LP
Retail

18. $3.8 million
The lead investors
● Travis and Kim McIntyre $1.8 million
● Group of 10 $2 million
Previous
Round

19. $5 million
Use of proceeds
● $3,000,000 completion of Phase 1 - Increasing production 5x to
5,500 kilos/year = $25 million/year in sales
● $2,000,000 - 12 month run-rate fixed costs and crops
*Qualify our valuation of $25,00,000 on TSX.v
This
Round

20. 20% stake
● Entry price
■ $0.50 per share
● Bonus
■ $1.00 warrants exercisable at $1.50 after 15 consecutive days of trading
over $1.50 within the 12 months post-closing
The
Offer

21. Market
Comparables
Name Symbol Market Cap
*CDN$
Share Price
*CDN$
Sales
Last Q
P/
Earnings
P/
Sales
Canopy Growth
Corp.
TSX:WEED $8.85Billion $39.82 $22 million nill 100x
Aphria Inc. TSXV:APH $2.4 billion $9.74 $28 million 47x 50x
Aurora Cannabis
Inc.
TSXV:ACB $3.6billion $6.24 $16 million nill 56x
Cronos Group TSXV:CRON $1.47 billion $7.91 $2.9 million 1193x 126x
Stigma
Pharmaceuticals
$120 million $1.5 million 20x

22. $25 million
$120 million
Post-money.Valuation
Q2 2019 Target Valuation

23. FAQ:
What is built to date and how much revenue will it generate?
Phase 1 22,000 that can generate $5,000,000 sales yearly
Have we sold any product?
No
Do we have R&D?
Yes. 2 years of full R&D with 35 strains CBD, THC Sativa, Indica and Mix
Do we have retail locations:?
Yes. 1 location is spec'd with approval from AGLC
Do we have acquisition targets?
Yes. For Brand and Consumer Product creation as well as a BC LP and an Alberta
extraction facility
When can I give you my money?